We used the CMAUP database [39], which includes approximately 48,000 phytochemicals, targeting the ATP-binding site of Type I JAK-1/JAK-2 inhibitors, like baricitinib, ruxolitinib, and fedratinib, all previously reported to counteract aging hallmarks in both normal and Hutchinson–Gilford Progeria Syndrome (HGPS) cells [19,20]. The gene discussed is JAK2; the disease is Hutchinson-Gilford progeria syndrome.